Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90003 in BRAF or RAS-mutated solid tumors
NCT02313012Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of cc-90003 in solid tumor and metastatic neoplasm, sponsored by Celgene Corporation. Primary endpoints: Summary of the adverse events (type, severity, and incidence) at 36 months, Dose Limiting Toxicities at 18 months and 8 more. Started Jan 2015; status: terminated.
02
Drugs
cc-90003
03
Conditions
solid tumormetastatic neoplasm
Beyond the preview
Go deeper on NCT02313012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313012.